MEDCAC Review of PGx Cancer Tests Finds Some Clinical Utility, More Evidentiary Gaps | GenomeWeb

By Turna Ray

Pharmacogenomic tests to guide treatment with Herceptin for breast cancer, Gleevec in chronic myelogenous leukemia, and Vectibix and Erbitux for colorectal cancer improve patient outcomes, an advisory panel for the Centers for Medicare and Medicaid Services decided last week. In its review of these and two other tests, however, the panel identified numerous evidence gaps that CMS and private payors would likely require before covering them more broadly.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.